Prothena Corporation (PRTA) Financials: History & Chart

Prothena Corporation plc(PRTA)

Biotechnology · Dublin, DU

$8.08-0.19 (-2.31%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Dublin, DU

67 employees

www.prothena.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gene G. Kinney

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	54.53M	1.01M	51.08M	21K	2.42M	4.42M	2.83M	2.12M	970K
Cost of Goods Sold	30.80M	0.00	918K	942K	28.94M	0.00	0.00	0.00	0.00
Gross Profit	23.73M	1.01M	50.17M	-921K	-26.52M	4.42M	2.83M	2.12M	970K
Gross Profit Margin	43.5%	100.0%	98.2%	-4385.7%	-1098.3%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	86.49M	22.11M	24.38M	26.29M	13.72M	89.04M	68.41M	67.02M	67.48M
Research & Development	64.95M	8.80M	12.63M	14.59M	28.94M	40.52M	50.81M	50.17M	50.72M
Selling, General & Administrative	49.45M	10.90M	12.67M	12.65M	13.24M	15.91M	17.60M	16.85M	16.76M
Operating Income (EBIT)	-62.76M	-21.10M	25.79M	-27.21M	-40.24M	-84.62M	-65.58M	-64.90M	-66.51M
Operating Margin	-115.1%	-2089.2%	50.5%	-129576.2%	-1666.3%	-1914.4%	-2319.0%	-3056.9%	-6857.0%
Income Before Tax (EBT)	-43.61M	-18.58M	32.72M	-21.58M	-36.17M	-80.97M	-61.37M	-59.50M	-59.84M
Interest Income	10.97M	2.55M	2.42M	2.65M	3.35M	3.79M	4.35M	5.39M	6.74M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	19.15M	2.52M	6.93M	5.63M	4.07M	3.65M	4.21M	5.40M	6.68M
Net Income	-43.99M	-18.58M	32.72M	-21.59M	-36.54M	-125.77M	-60.20M	-57.96M	-59.00M
Income Tax Expense	384K	2K	1K	10K	371K	44.80M	-1.18M	-1.54M	-835K
Net Profit Margin	-80.7%	-1839.9%	64.1%	-102804.8%	-1513.1%	-2845.4%	-2128.5%	-2729.9%	-6082.6%
EBITDA	-60.29M	-20.72M	26.71M	-26.27M	-40.01M	-84.39M	-65.36M	-64.68M	-66.29M
EBITDA Margin	-110.6%	-2051.5%	52.3%	-125090.5%	-1656.8%	-1909.3%	-2311.1%	-3046.4%	-6833.7%
Depreciation & Amortization	2.47M	381K	918K	942K	229K	225K	223K	221K	226K
EPS Basic	-0.83	-0.36	0.61	-0.40	-0.68	-2.34	-1.12	-1.08	-1.10
EPS Diluted	-0.84	-0.36	0.60	-0.40	-0.68	-2.34	-1.12	-1.08	-1.10
Weighted Average Basic Shares	52.15M	52.15M	53.71M	53.83M	53.83M	53.83M	53.83M	53.81M	53.79M
Weighted Average Diluted Shares	52.15M	52.15M	54.11M	53.83M	53.83M	53.83M	53.83M	53.81M	53.79M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	9.68M	135.16M	91.37M	53.91M	200.58M	853K	814K	955K
Cost of Goods Sold	3.70M	0.00	0.00	0.00	0.00	74.88M	50.84M	101.18M
Gross Profit	5.98M	135.16M	91.37M	53.91M	200.58M	-74.03M	-50.02M	-100.23M
Gross Profit Margin	61.8%	100.0%	100.0%	100.0%	100.0%	-8678.9%	-6145.2%	-10495.1%
Total Operating Expenses	190.54M	289.72M	282.41M	185.46M	128.60M	38.70M	35.67M	143.66M
Research & Development	134.85M	222.52M	220.57M	135.56M	82.28M	75.09M	50.84M	101.18M
Selling, General & Administrative	59.39M	67.20M	61.84M	49.90M	46.32M	38.70M	35.74M	42.48M
Operating Income (EBIT)	-184.56M	-154.56M	-191.04M	-131.56M	71.97M	-112.73M	-85.70M	-158.85M
Operating Margin	-1905.8%	-114.4%	-209.1%	-244.1%	35.9%	-13216.2%	-10527.9%	-16634.0%
Income Before Tax (EBT)	-200.83M	-128.93M	-160.48M	-125.61M	71.92M	-110.86M	-77.30M	-156.12M
Interest Income	14.14M	25.82M	31.01M	6.35M	42K	1.37M	8.20M	6.39M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	3.70M
Other Income/Expense	-16.27M	25.63M	30.56M	5.95M	-54K	1.87M	8.40M	2.74M
Net Income	-244.09M	-122.31M	-147.03M	-116.95M	66.97M	-111.14M	-77.68M	-155.65M
Income Tax Expense	43.26M	-6.62M	-13.45M	-8.66M	4.95M	283K	379K	-470K
Net Profit Margin	-2520.6%	-90.5%	-160.9%	-217.0%	33.4%	-13029.8%	-9542.6%	-16297.9%
EBITDA	-180.86M	-153.67M	-190.11M	-130.81M	73.09M	-111.22M	-84.13M	-155.64M
EBITDA Margin	-1867.6%	-113.7%	-208.1%	-242.7%	36.4%	-13038.7%	-10335.7%	-16297.3%
Depreciation & Amortization	3.70M	893K	928K	744K	1.11M	1.51M	1.56M	3.22M
EPS Basic	-4.53	-2.27	-2.76	-2.47	1.51	-2.78	-1.95	-3.93
EPS Diluted	-4.53	-2.27	-2.76	-2.47	1.38	-2.78	-1.95	-3.93
Weighted Average Basic Shares	53.83M	53.77M	53.22M	47.37M	44.23M	39.91M	39.88M	39.56M
Weighted Average Diluted Shares	53.83M	53.77M	53.22M	47.37M	48.46M	39.91M	39.88M	39.56M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.